One of the key patient barriers is fear of hypoglycaemia, which can be managed by appropriate training, introduction of blood glucose self-monitoring (50,62), use of basal insulin analogues (62) and translation of PD concepts into practical clinical dosing regimens. The gene discussed is INS; the disease is Hypoglycemia.